Mestag was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer.
Our goal is to bring transformative therapies to patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. The founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from world-leading institutes in the US and UK including University of Oxford, Harvard Medical School, the Broad Institute, Cold Spring Harbor and Brigham and Women’s Hospital.
We are progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology and are supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is based in Cambridge, UK.
We are actively assembling a driven, motivated team to discover and develop new therapeutics.
We are hiring! Reach out to learn more about opportunities to join our team.
Our goal is to bring transformative therapies to patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. The founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from world-leading institutes in the US and UK including University of Oxford, Harvard Medical School, the Broad Institute, Cold Spring Harbor and Brigham and Women’s Hospital.
We are progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology and are supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is based in Cambridge, UK.
We are actively assembling a driven, motivated team to discover and develop new therapeutics.
We are hiring! Reach out to learn more about opportunities to join our team.
Location: United Kingdom
Employees: 11-50
Total raised: $75.99M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Sheatrust ... | sheatrustc... |
| - | Forbion | forbion.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.03.2026 | - | $40M | Johnson &a... |
| 28.08.2024 | Grant | $1.98M | - |
| 04.08.2021 | Seed | $34.01M | Forbion |
Mentions in press and media 19
| Date | Title | Description |
| 21.03.2026 | Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies | Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-20... |
| 17.03.2026 | Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic | Mestag Therapeutics, a biotech company focused on fibroblast immunology, has announced the closing of a $40 million financing round, bringing its total funding to more than $95 million. The round was backed by SV Health Investors, Johnson &... |
| 17.03.2026 | Mestag Therapeutics Raises $40M in Financing | Mestag Therapeutics, a Cambridge, UK-based biotech company harnessing fibroblast immunology to develop treatments for cancer and inflammatory diseases, closed a $40m financing. Backers includwed SV Health Investors, Johnson & Johnson, t... |
| 04.03.2025 | Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer | Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, today announced that Matthew Sleeman, PhD, has been appointed Chief Scientific Officer. “Ma... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
| 08.10.2024 | Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases | – Exclusively deploys Mestag’s proprietary RAFT platform to interrogate the pathogenic role of fibroblasts in inflammatory disease for novel target discovery Cambridge, UK, October 8, 2024 – Mestag Therapeutics (“Mestag”), a biotech company... |
| 29.08.2024 | Biocon Biologics and Mestag Therapeutics: Pioneering Paths in Biosimilars and Cancer Treatment | In the world of biotechnology, innovation is the lifeblood. Two companies, Biocon Biologics and Mestag Therapeutics, are carving their niches in this dynamic landscape. Their recent developments signal a shift in how we approach treatment f... |
| 28.08.2024 | Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300 | – Innovate UK, part of UK Research and Innovation, is investing £12 million in innovation projects to advance next-generation immunotherapies for cancer, of which £1.5 million has been awarded to Mestag – Bispecific antibody MST-0300 is a f... |
| 28.08.2024 | Mestag Therapeutics Receives £1.5M Grant from Innovate UK’s Cancer Therapeutics Program | Mestag Therapeutics, a Cambridge, MA-based biotech company harnessing new insights into fibroblast-immune interactions, received a £1.5M Grant from Innovate UK’s Cancer Therapeutics Program. The company intends to use the amount to accelera... |
Show more